220 related articles for article (PubMed ID: 12946754)
1. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study.
Salem N; Simonian-Sauve M; Rosello R; Alzieu C; Gravis G; Maraninchi D; Bladou F
Radiother Oncol; 2003 Feb; 66(2):159-65. PubMed ID: 12648787
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two iodine-125 brachytherapy implant techniques for the treatment of lung tumor: Preplanning and intraoperative planning.
Li R; Ying Z; Yuan Y; Lin Q; Dai J; Xu R; Geng B; Han M
Brachytherapy; 2019; 18(1):87-94. PubMed ID: 30482623
[TBL] [Abstract][Full Text] [Related]
4. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
6. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
[TBL] [Abstract][Full Text] [Related]
7. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study.
Ohashi T; Yorozu A; Saito S; Tanaka N; Katayama N; Kojima S; Maruo S; Kikuchi T; Dokiya T; Fukushima M; Yamanaka H
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):141-9. PubMed ID: 26279031
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
10. Comparison of preplanning and intraoperative planning for I-125 prostate brachytherapy.
Yoshida K; Ohashi T; Yorozu A; Toya K; Nishiyama T; Saito S; Hanada T; Shiraishi Y; Shigematsu N
Jpn J Clin Oncol; 2013 Apr; 43(4):383-9. PubMed ID: 23315386
[TBL] [Abstract][Full Text] [Related]
11. Permanent prostate brachytherapy using high V150.
Serrano NA; Pham HT; Narayanan S; Badiozamani KR
Pract Radiat Oncol; 2015; 5(3):e201-e206. PubMed ID: 25413406
[TBL] [Abstract][Full Text] [Related]
12. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
[TBL] [Abstract][Full Text] [Related]
13. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
[TBL] [Abstract][Full Text] [Related]
14. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
15. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.
Roeloffzen EM; Battermann JJ; van Deursen MJ; Monninkhof EM; Visscher MI; Moerland MA; van Vulpen M
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1072-9. PubMed ID: 20615621
[TBL] [Abstract][Full Text] [Related]
16. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
18. [The French preliminary experience of the use of a seed-projector for exclusive iodine 125 prostate brachytherapy: feasibility and acute toxicity].
Pommier P; Delannes M; LeFloch O; Bernier V; Baron MH; Thomas L; Malet C; Bonnet J; Louisot P; Aletti P; Goubard O; Chemin A; Chirat F; Lebivic S; Montbarbon X; Bachaud JM; Votron L; Lasbareilles O; Desmettre O; Bringeon G; Gassa F; Peiffert D
Cancer Radiother; 2006 Dec; 10(8):559-64. PubMed ID: 16959520
[TBL] [Abstract][Full Text] [Related]
19. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
[TBL] [Abstract][Full Text] [Related]
20. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
